Targeting the LOX-1 scavenger receptor for therapeutics and diagnostics

Expert Opin Ther Targets. 2026 Sep 28. doi: 10.1080/14728222.2026.2738346. Online ahead of print.ABSTRACTINTRODUCTION: Vascular dysfunction underpins major pathologies including cardiovascular disease, stroke and cancer. Lipid particle (LP) recognition, processing and metabolism impacts on vascular

S Sreenivasan Ponnambalam

Dapagliflozin Alone or Combined With Semaglutide: Cardiovascular and Renal Outcomes Among Patients With Type 2 Diabetes Mellitus in a 6-Month Real-World Retrospective Cohort Study in Saudi Arabia

J ASEAN Fed Endocr Soc. 2026 Aug;41(2):75-84. doi: 10.15605/jafes.041.02.6171. Epub 2026 Aug 13.ABSTRACTINTRODUCTION: Type 2 diabetes mellitus (T2DM) is a growing global health concern linked to increased cardiovascular and renal complications. Two emerging therapeutic classes, sodium-glucose cotran

R Rasmah Alharajin

Lysyl oxidase (LOX)-mediated remodeling of the extracellular matrix

FEBS Lett. 2026 Sep 28. doi: 10.1002/1873-3468.70472. Online ahead of print.ABSTRACTThe lysyl oxidase (LOX) family of enzymes drives extracellular matrix remodeling by oxidizing collagen, elastin, and fibronectin, promoting covalent cross-link formation. This activity regulates tissue architecture a

F Fernando Rodríguez-Pascual

Diagnosis of familial hypercholesterolaemia through population screening

Expert Rev Cardiovasc Ther. 2026 Sep 27. doi: 10.1080/14779072.2026.2741509. Online ahead of print.ABSTRACTINTRODUCTION: Familial hypercholesterolemia (FH) is an autosomal dominant disorder characterized by raised levels of low-density lipoprotein cholesterol (LDL-C) and premature cardiovascular dis

A Anthony S Wierzbicki

A Prospective Cohort Study of Hard-to-Heal Chronic Foot and Leg Wounds Followed for up to 20 Weeks After Initiation of ReGenerating Tissue Agents (RGTA) Technology as an Add-on to Optimal Local Care

Int Wound J. 2026 Oct;23(10):e71057. doi: 10.1111/iwj.71057.ABSTRACTReGenerating Tissue Agents (RGTA, trade name CACIPLIQ20) contain a structural analogue of heparan sulfates (HSs) that promotes tissue regeneration in hard-to-heal chronic wounds resistant to the best standard of care for 6 months or

S Serge Ynesta